Last reviewed 2026-06-01 · How we verify

Dipipanon (DIPIPANONE)

Phase 2 active Small molecule ✓ Verified Jun 2026

Dipipanon (generic name: DIPIPANONE) is a drug. It is currently in Phase 2 development.

Dipipanon works by binding to opioid receptors in the brain, altering the perception of pain.

Dipipanon is a small molecule with the synonyms ACSCN-9622, DIPIPANONA, DIPIPANONE, IDS-ND-017, PHENYLPIPERONE, and PIPERIDYLAMIDONE.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DIPIPANONE
Modality	Small molecule
Therapeutic area	Pain
Phase	Phase 2

Mechanism of action

Imagine your brain has special locks that control how you feel pain. Dipipanon is a key that fits into these locks, changing the way the locks work and reducing the sensation of pain. This helps to relieve pain and discomfort, but it can also have side effects and interact with other medications.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dipipanon CI brief — competitive landscape report
Dipipanon updates RSS · CI watch RSS

Frequently asked questions about Dipipanon

What is Dipipanon?

Dipipanon (DIPIPANONE) is a Small molecule drug.

How does Dipipanon work?

Dipipanon works by binding to opioid receptors in the brain, altering the perception of pain.

What is the generic name of Dipipanon?

DIPIPANONE is the generic (nonproprietary) name of Dipipanon.

What development phase is Dipipanon in?

Dipipanon is in Phase 2.

Therapeutic area: All drugs in Pain

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing